AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00732511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
Study NCT00732511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol extended release
Description: tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
Study NCT00075400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00075400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00346073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
Study NCT00346073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL®
Description: Sanofi Pasteur
Study NCT02195024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI group
Description: • All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
Study NCT00603109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: rimonabant capsule 20 mg per day PO for 6 months
Study NCT00603109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects take 20 mg placebo capsule one a day PO for 6 months
Study NCT02270619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
Study NCT02270619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Description: Partial night sleep deprivation by staying awake from 23:00 to 03:00
Study NCT02270619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline as IV bolus
Study NCT02270619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline as IV bolus
Study NCT02270619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uninterrupted sleep
Description: Uninterrupted sleep from 23:00 to 07:00
Study NCT02270619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Uninterrupted sleep
Description: Uninterrupted sleep from 23:00 to 07:00
Study NCT02275078 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: COPD self-management using an action plan
Description: Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
Study NCT02275078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Telesystem-Phone self-assessment/reporting system
Description: Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
Study NCT02275078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse case manager support
Description: Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
Study NCT04342871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT
Description: Customized communication guidance to help parents with cancer talk about their cancer with their children.
Study NCT04620044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaledo game
Description: Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
Study NCT04620044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
Study NCT04620044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
Study NCT03012087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHealthyChoices
Description: My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
Study NCT03012087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Risk Assessment
Description: The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
Study NCT02031562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chiropractic
Description: chiropractic
Study NCT02031562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy
Study NCT02004496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Consilium
Description: Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
Study NCT01511276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
Study NCT01511276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mainly exercise induced weight loss
Description: Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day.
Study NCT02808754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic > 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
Study NCT03832491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home based therapy
Description: Airway clearence techniques
Study NCT03832491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game and home based therapy
Description: Game based approach programme and airway clearence techniques
Study NCT04391348 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine
Description: Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
Study NCT03103802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-oral digital scanner and extra-oral digital scanner
Description: intra-oral and extra-oral digital scanners used to obtain digital models
Study NCT02180555 — intervention group
Intervention type: OTHER
Intervention: Oral glucose tolerance test
Study NCT01611974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Tablet for oral administration
Study NCT03854864 — intervention group
Intervention type: OTHER
Intervention: survey
Description: to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
Study NCT01620931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5469754
Description: Single ascending doses, iv or sc
Study NCT01620931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses, iv or sc
Study NCT02116556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
Study NCT02116556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
Study NCT02116556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin PO 1200 mg/day for 90 days
Study NCT00518037 — intervention group
Intervention type: BEHAVIORAL
Intervention: surveys
Description: anxiety surveys
Study NCT02250820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Nasal administration
Study NCT02250820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Description: Oral administration
Study NCT02250820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral placebo will be cherry syrup
Study NCT02250820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Placebo
Description: Nasal placebo will be nasally atomized saline
Study NCT02176473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy
Description: The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/.
Study NCT01423409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pictorial VAS
Description: Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
Study NCT01423409 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: usual VAS
Description: usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
Study NCT02603874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Tape
Description: Comparing procedures using Target Tape against procedures not using Target Tape
Study NCT04464395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006
Description: Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.
Study NCT04464395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Participants will receive standard of care treatment only.
Study NCT02257372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC DPI
Description: The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
Study NCT02257372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
Study NCT02257372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA medication
Description: Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
Study NCT02257372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
Study NCT00003535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT03194282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insole
Description: The subjects are randomly assigned to assess balance capacity either with or without insole.
Study NCT03194282 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: insole
Description: The subjects are randomly assigned to assess balance capacity either with or without insole.
Study NCT02672436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F703
Description: Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
Study NCT02672436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENERGI-F703 matched vehicle
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Study NCT02289742 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lenses
Study NCT02289742 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lenses
Study NCT02289742 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A sphere contact lenses
Study NCT04136873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231
Study NCT04136873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231
Study NCT01366547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
Study NCT01366547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
Study NCT01366547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir 600 mg/lamivudine 300 mg
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Study NCT01030770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
Study NCT01030770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
Study NCT02952157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine jelly application
Study NCT02952157 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline application
Study NCT01279577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose TSO
Description: Low dose TSO suspension
Study NCT01279577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose TSO
Description: Medium dose TSO suspension
Study NCT01279577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose TSO
Description: High dose TSO suspension
Study NCT01279577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study NCT02211729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
Description: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
Study NCT02211729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin
Description: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
Study NCT00914927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
Study NCT00914927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
Study NCT00914927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo or inactive substance once a day for up to 7 days
Study NCT00914927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or inactive substance once a day for up to 7 days
Study NCT01323725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-based financial incentives
Description: Team-based financial incentives for smoking cessation at 6 month post-quit date.
Study NCT03844984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine full dose
Description: This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
Study NCT03844984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg
Study NCT03844984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg
Study NCT03844984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: This group will receive normal saline 10 mL
Study NCT03844984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine half dose
Description: This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
Study NCT03844984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
Study NCT00527475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg. given as an intraocular injection
Study NCT00527475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg. given as an intraocular injection
Study NCT00527475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
Study NCT02316340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 400mg by mouth daily
Study NCT02316340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 600mg by mouth daily
Study NCT02316340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: 160 mg by mouth daily